Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058123 · ClinicalTrials.gov registry record · Phase 2
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00058123 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 55 participants.
The verdict
NCT00058123, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how poly-ICLC works in treating patients with recurrent, progressive, or relapsed anaplastic glioma.
Interventions
- DRUG poly ICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2003-03-07 |
| Est. Completion | 2009-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058123
The ClinicalTrials.gov registry entry for NCT00058123 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which poly ICLC is the first listed.
NCT00058123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058123 about?
NCT00058123 is a clinical study titled "Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma". RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how poly-ICLC works in treating patients with recurrent, progressive, or relapsed anaplastic glioma.
What is the current status of trial NCT00058123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2003-03-07. Estimated completion is 2009-01-02.
What interventions are being tested in trial NCT00058123?
The interventions under investigation include: poly ICLC (DRUG).
Who is sponsoring clinical trial NCT00058123?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.